These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 16214121)

  • 21. Functional co-expression of CYP2D6 and human NADPH-cytochrome P450 reductase in Escherichia coli.
    Pritchard MP; Glancey MJ; Blake JA; Gilham DE; Burchell B; Wolf CR; Friedberg T
    Pharmacogenetics; 1998 Feb; 8(1):33-42. PubMed ID: 9511179
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human liver cytochrome P450 2D6 genotype, full-length messenger ribonucleic acid, and activity assessed with a novel cytochrome P450 2D6 substrate.
    McConnachie L; Bodor M; Kowdley K; Levy A; Tung B; Thummel K; Phillips B; Bajpai M; Chi V; Esmay JD; Shen DD; Ho RJ
    Clin Pharmacol Ther; 2004 Apr; 75(4):282-97. PubMed ID: 15060507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enantioselectivity of bunitrolol 4-hydroxylation is reversed by the change of an amino acid residue from valine to methionine at position 374 of cytochrome P450-2D6.
    Narimatsu S; Kato R; Horie T; Ono S; Tsutsui M; Yabusaki Y; Ohmori S; Kitada M; Ichioka T; Shimada N; Kato R; Ishikawa T
    Chirality; 1999; 11(1):1-9. PubMed ID: 9914647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Production of human cytochrome P450 2D6 drug metabolites with recombinant microbes--a comparative study.
    Geier M; Braun A; Emmerstorfer A; Pichler H; Glieder A
    Biotechnol J; 2012 Nov; 7(11):1346-58. PubMed ID: 22930520
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Site-Directed Mutagenesis of Cytochrome P450 2D6 and 2C19 Enzymes: Expression and Spectral Characterization of Naturally Occurring Allelic Variants.
    Dong AN; Pan Y; Palanisamy UD; Yiap BC; Ahemad N; Ong CE
    Appl Biochem Biotechnol; 2018 Sep; 186(1):132-144. PubMed ID: 29524040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450.
    Chen CS; Jounaidi Y; Waxman DJ
    Drug Metab Dispos; 2005 Sep; 33(9):1261-7. PubMed ID: 15919850
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events.
    Toscano C; Klein K; Blievernicht J; Schaeffeler E; Saussele T; Raimundo S; Eichelbaum M; Schwab M; Zanger UM
    Pharmacogenet Genomics; 2006 Oct; 16(10):755-66. PubMed ID: 17001295
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Establishment of ten strains of genetically engineered Salmonella typhimurium TA1538 each co-expressing a form of human cytochrome P450 with NADPH-cytochrome P450 reductase sensitive to various promutagens.
    Yamazaki Y; Fujita K; Nakayama K; Suzuki A; Nakamura K; Yamazaki H; Kamataki T
    Mutat Res; 2004 Aug; 562(1-2):151-62. PubMed ID: 15279838
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human NADPH-cytochrome p450 reductase overexpression does not enhance the aerobic cytotoxicity of doxorubicin in human breast cancer cell lines.
    Ramji S; Lee C; Inaba T; Patterson AV; Riddick DS
    Cancer Res; 2003 Oct; 63(20):6914-9. PubMed ID: 14583491
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies.
    Kanebratt KP; Andersson TB
    Drug Metab Dispos; 2008 Jul; 36(7):1444-52. PubMed ID: 18385292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A silent mutation (2939G>A, exon 6; CYP2D6*59) leading to impaired expression and function of CYP2D6.
    Toscano C; Raimundo S; Klein K; Eichelbaum M; Schwab M; Zanger UM
    Pharmacogenet Genomics; 2006 Oct; 16(10):767-70. PubMed ID: 17001296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytochrome P450 3A, NADPH cytochrome P450 reductase and cytochrome b5 in the upper airways in horse.
    Tydén E; Olsén L; Tallkvist J; Tjälve H; Larsson P
    Res Vet Sci; 2008 Aug; 85(1):80-5. PubMed ID: 17980394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bimolecular fluorescence complementation analysis of cytochrome p450 2c2, 2e1, and NADPH-cytochrome p450 reductase molecular interactions in living cells.
    Ozalp C; Szczesna-Skorupa E; Kemper B
    Drug Metab Dispos; 2005 Sep; 33(9):1382-90. PubMed ID: 15980100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of phenylalanine 120 on cytochrome P450 2D6 catalytic selectivity and regiospecificity: crucial role in 7-methoxy-4-(aminomethyl)-coumarin metabolism.
    Keizers PH; Lussenburg BM; de Graaf C; Mentink LM; Vermeulen NP; Commandeur JN
    Biochem Pharmacol; 2004 Dec; 68(11):2263-71. PubMed ID: 15498516
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Metabolic Activities Catalyzed by Human Cytochrome P450 (CYP) 2D6 and CYP3A Subfamily Members and Effect of Various Compounds, Including Endogenous Steroid Hormones, on These Activities].
    Niwa T
    Yakugaku Zasshi; 2024; 144(2):197-202. PubMed ID: 38296497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diversity in mechanisms of substrate oxidation by cytochrome P450 2D6. Lack of an allosteric role of NADPH-cytochrome P450 reductase in catalytic regioselectivity.
    Hanna IH; Krauser JA; Cai H; Kim MS; Guengerich FP
    J Biol Chem; 2001 Oct; 276(43):39553-61. PubMed ID: 11509577
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stable expression of human cytochrome P450 2D6*10 in HepG2 cells.
    Zhuge J; Yu YN; Wu XD
    World J Gastroenterol; 2004 Jan; 10(2):234-7. PubMed ID: 14716830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of CYP2D6 polymorphism on 3,4-methylenedioxymethamphetamine ('Ecstasy') cytotoxicity.
    Carmo H; Brulport M; Hermes M; Oesch F; Silva R; Ferreira LM; Branco PS; Boer Dd; Remião F; Carvalho F; Schön MR; Krebsfaenger N; Doehmer J; Bastos Mde L; Hengstler JG
    Pharmacogenet Genomics; 2006 Nov; 16(11):789-99. PubMed ID: 17047487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ascorbic acid and alpha-tocopherol down-regulate apolipoprotein A-I gene expression in HepG2 and Caco-2 cell lines.
    Mooradian AD; Haas MJ; Wadud K
    Metabolism; 2006 Feb; 55(2):159-67. PubMed ID: 16423621
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potent inhibition of MAO mediated propranolol metabolism by dimethyl sulfoxide in Hep G2 cells.
    Steiner A; Walle T
    Res Commun Chem Pathol Pharmacol; 1992 Mar; 75(3):373-6. PubMed ID: 1509206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.